April 17–22 is Oral, Head, and Neck Cancer Awareness Week. The ADA advises that, while most cases of oral cancer affect people who use tobacco and/or drink heavily, more than a quarter of oral cancers occur in people who do not smoke and have no other risk factors. In order to help detect irregularities, Zila Pharmaceuticals Inc (manufacturer and marketer of the ViziLite® Plus Oral Lesion Identification and Marking System) urges patients to see a dentist for a potentially life-saving oral cancer exam.

“America’s dentists and hygienists are performing heroic acts every day,” says Dave Barshis, Zila Pharmaceuticals, vice president and general manager. “They are putting a new light on oral cancer and saving lives with early detection of this killer disease and its pre-cancer warning signs. During Oral, Head and Neck Cancer Awareness Week, we urge everyone to see their dentist for a comprehensive screening exam that includes ViziLite Plus.”

ViziLite Plus is indicated for use in patients who are at increased risk for oral cancer. If ViziLite reveals an abnormality, TBlue630 is   used to mark suspicious lesions for further evaluation.